Oral squamous cell carcinoma
Conditions
Interventions
Docetaxel is administered intravenously for 1 h on day1. After completion of the docetaxel infusion, nedaplatin is administered intravenously for another hour followed by 1,000 ml or more hydration. T
Sponsors
Chubu research group on oral cancer
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Case with oral squamous cell carcinoma histologically, (2) age between 20 and 80 years (patients aged >80 years were allowed if major organs functions was preserved), (3) Karnofsky Performance Status (PS) score of 2 or less (4) adequate bone marrow function (5) adequate hepatic function (6) adequate renal function (7) written informed consent.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had active infections, active second malignancy, severe heart diseases, interstitial pneumonia or lung fibrosis, severe pleural effusion or pericardial effusion that required drainage, fever more than or equal to 38 C, symptomatic brain metastasis, severe psychological disease, and possible pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of outpatient chemotherapy with docetaxel and nedaplatin for patients with unresectable or recurrent oral squamous cell carcinoma | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical and histopathological effect of outpatient chemotherapy with docetaxel and nedaplatin for patients with unresectable or recurrent oral squamous cell carcinoma | — |
Countries
Japan
Contacts
Public ContactHiroshi Kurita
Shinshu University School of Medicine Department of Dentistry and Oral surgery
Outcome results
None listed